Collegium Pharmaceutical (COLL) Interest Expenses (2015 - 2026)

Collegium Pharmaceutical's Interest Expenses history runs 11 years deep, the most recent figure standing at $15.9 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 23.7% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $77.4 million (changed 0.05% YoY), while the FY2025 annual figure was $82.3 million, up 11.27% from the prior year.
• Interest Expenses was $15.9 million for Q1 2026 at Collegium Pharmaceutical, down from $19.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $22.7 million in Q4 2024 to a low of $5.8 million in Q1 2022.
• Historically, Interest Expenses has averaged $18.7 million across 5 years, with a median of $19.3 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses jumped 332.52% in 2022, then declined 28.71% in 2024.
• A 5-year view of Interest Expenses shows it stood at $20.6 million in 2022, then retreated by 6.29% to $19.3 million in 2023, then advanced by 17.49% to $22.7 million in 2024, then declined by 14.84% to $19.3 million in 2025, then dropped by 17.78% to $15.9 million in 2026.
• The last three Interest Expenses figures came in at $15.9 million (Q1 2026), $19.3 million (Q4 2025), and $21.8 million (Q3 2025), per Business Quant data.